SCHEMBL2834290

SCHEMBL2834290

CCCn1c(C)c(C(=O)O)c2ccccc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
HPGD P15428 4/20 0.49
ALDH1A1 P00352 3/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CNR2 P34972 9/20 0.48
CNR1 P21554 6/20 0.48
MAPT P10636 2/20 0.48
CYP1A2 P05177 2/20 0.48
TSHR P16473 2/20 0.48
MAPK1 P28482 2/20 0.48
CYP2C19 P33261 2/20 0.48
NPC1 O15118 1/20 0.48
NR1I2 O75469 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
GMNN O75496 1/20 0.47
LMNA P02545 1/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830643 0.91 TDP1 (0.62) MEN1KMT2AHPGDALDH1A1TDP1
SCHEMBL2835070 0.90 L3MBTL1 (0.56) MEN1KMT2AALDH1A1TDP1L3MBTL1
SCHEMBL2834167 0.84 ALDH1A1 (0.63) MEN1KMT2AHPGDALDH1A1TDP1
SCHEMBL2831869 0.84 MAPT (0.44) MEN1KMT2AHPGDALDH1A1TDP1
SCHEMBL2832041 0.84 ALDH1A1 (0.52) MEN1KMT2AHPGDALDH1A1TDP1
SCHEMBL2831355 0.82 ALDH1A1 (0.65) MEN1KMT2AHPGDALDH1A1TDP1
SCHEMBL3350444 0.82 SMN1; SMN2 (0.58) MEN1KMT2AHPGDALDH1A1MAPT
SCHEMBL2832139 0.81 CNR2 (0.55) MEN1KMT2AHPGDALDH1A1TDP1
SCHEMBL2831862 0.81 CNR2 (0.46) MEN1KMT2AHPGDALDH1A1CNR2
SCHEMBL2832448 0.79 RAB9A (0.49) MEN1KMT2AHPGDALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MEN1 2461/4885KMT2A 891/4885HPGD 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.